Interestingly, the breast cancer susceptibility gene (BRCA) 2 mutation status is associated with responsiveness to PD-1 mAb therapy [83], while no correlation was found between BRCA2 and avelumab’s clinical effect on ovarian cancer [64]. The gene discussed is PDCD1; the disease is ovarian cancer.